Supko, Jeffrey G.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 11,486

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research

Genomics, phytochemicals, and oxidative stressBioactive Compounds and Antitumor Agents

Cited by 236

A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors

Jonker, D. J., Stephenson, J., Edenfield, W. J., Supko, J. G., Li, Y., Li, W., Hitron, M., Leggett, D., Kerstein, D., & Li, C. (2014) · Journal of Clinical Oncology

Cancer Cells and MetastasisMesenchymal stem cell research

Cited by 19